Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis

Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis

(2020) Madeline Bross et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis

(2019) Rachael McCool et al.   Multiple Sclerosis and Related Disorders

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

(2019) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

(2019) Giancarlo Comi et al.   LANCET NEUROLOGY

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

(2018) Alexander Rae-Grant et al.   NEUROLOGY

Multiple sclerosis

(2018) Jiwon Oh et al.   CURRENT OPINION IN NEUROLOGY

Update on disease-modifying therapies for multiple sclerosis

(2017) Diana L Vargas et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

(2017) Tjalf Ziemssen et al.   Therapeutic Advances in Neurological Disorders

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

(2017) Cristina Guarnera et al.   Therapeutics and Clinical Risk Management

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis

(2016) María Rosario Blasco et al.   JOURNAL OF NEUROLOGY

Classification, diagnosis, and differential diagnosis of multiple sclerosis

(2015) Ilana Katz Sand   CURRENT OPINION IN NEUROLOGY

Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis

(2015) Gert van Valkenhoef et al.   Research Synthesis Methods

Alemtuzumab for the treatment of relapsing–remitting multiple sclerosis

(2014) Carrie M Hersh et al.   Immunotherapy

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

(2014) T. L. Vollmer et al.   JOURNAL OF NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Graphical Tools for Network Meta-Analysis in STATA

(2013) Anna Chaimani et al.   PLoS One

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials

(2011) Makiko N Mieno et al.   BMC Medical Research Methodology

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY